MedTrace Logo

Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients

NCT04980352 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-07-28

No results posted yet for this study

Summary

This study aims to determine the clinical effectiveness of multi-dimensional signatures in predicting response and prognosis of lung cancer patients. The study is a multi-center perspective research of treatment planning for patients with lung cancer. To characterize clinical effectiveness, the progression-free survival (PFS) and overall survival (OS) impacts of multi-dimensional signatures will be estimated.

Conditions

  • Response
  • Prognosis

Interventions

OTHER

real world treatment by doctors

real world treatment by doctors

Sponsors & Collaborators

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Wuhan TongJi Hospital

    collaborator OTHER

  • Wuhan University

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-12-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04980352 on ClinicalTrials.gov